Basic Science in Medicine



Similar documents
How To Expand Hematopoietic Stem Cells

Human Umbilical Cord Blood CD34 + Progenitor Cell Care Manual

Processing & Utilization of Cord Blood for Transplant

Human Umbilical Cord-derived Multipotent Mesenchymal Stromal Cells (huc-msc) Handling Instructions

Improved Ex Vivo Expansion of Functional CD34 + Cells Using Stemline II Hematopoietic Stem Cell Expansion Medium

Equine Stem Cells. Sources, Processing, Expansion, Storage and Shipping

Review. Cord blood as an alternative source of haemopoietic stem cells. J. Hows, A. Nicol, P. Denning-Kendall, C. Donaldson, M. Nieda & B.

STEMCELL Quality Control Kits

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE

Cord Blood Re-imagined The use of cord blood stem cells for clinical applications and medical innovations

The Power & Potential of Cord Blood

Stem Cells in Umbilical Cord Blood: A Review

Cord derived MSC-Like Placenta derived Membranes- Matrix- Cells- MSC-like,

BioResearch. Hematopoietic and Immune Cell Products Essential Tools for Hematopoietic Research

Stem Cell Research: Adult or Somatic Stem Cells

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life

STEM CELL FELLOWSHIP

Transmedcon Ahmedabad, Gujarat November 14-16, 2014

3D Cell Culture mimsys G

NCL Method ITA-6. Leukocyte Proliferation Assay

Xiubo Fan 1,FlorencePHGay 2,FrancescaWILim 3,JustinaMLAng 2,PatPYChu 3,SudiptoBari 3 and William YK Hwang 2,3*

Umbilical Cord Blood Stem Cells - A Comparative Analysis of Differential Stromal Cell. Lines Used to Support Natural Killer Cell Development

HUMAN MESENCHYMAL STEM CELLS AS BASIC TOOLS FOR TISSUE ENGINEERING: ISOLATION AND CULTURE

Stem cells possess 2 main characteristics: Sources of pluripotent stem cells: -Long-term self renewal. -The inner cell mass of the blastocyst.

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

Stem Cell Transplantation

The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke

低 剂 量 辐 射 对 脐 血 T 淋 巴 细 胞 膜 分 子 表 达 的 影 响 EFFECT OF LOW DOSE IRRADIATION ON EXPRESSION OF MEMBRANE MOLECULES OF T LYMPHOCYTES IN CORD BLOOD

Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between

So, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today.

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

Ficoll-Paque PREMIUM Ficoll-Paque PREMIUM Ficoll-Paque PREMIUM 1.073

Proliferation/Potency Assays: Is there more to CD34 and CFU?

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine.

Stem Cell Quick Guide: Stem Cell Basics

Current Issues in Stem Cell Technologies. Lance D. Trainor, MD OneBlood, Inc.

Detecting primitive hematopoietic stem cells in total nucleated and mononuclear cell fractions from umbilical cord blood segments and units

Umbilical Cord Blood Stem Cells Current Status & Future Potential

Mesenchymal Stem Cells

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

Chapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified)

THE INFLUENCE OF TISSUE (IN)COMPATIBILITY IN UMBILICAL CORD BLOOD TRANSPLANTATION

Enumeration and Viability of Nucleated Cells from Bone Marrow, Cord Blood, and Mobilized Peripheral Blood

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Natasha Kekre, 1 Jennifer Philippe, 2 Ranjeeta Mallick, 3 Susan Smith, 2 and David Allan 1,2,4. 1. Introduction

AAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Human Adult Mesothelial Cell Manual

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Mobilisation, Isolation and Coculture of Haematopoietic Stem Cells

The Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central

Biotechnology. Srivatsan Kidambi, Ph.D.

Cord Blood Bank Business Plan

HyStem. Hydrogels CELLULAR MATRICES FOR TRANSLATIONAL RESEARCH. esibio.com

Prostaglandin E2 Enhances Human Cord Blood Stem. Cell Xenotransplants and Shows Long-Term Safety. in Preclinical Nonhuman Primate Transplant Models

Cord Blood: Research Progress and Future Promise

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine

Cord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program

How To Treat Leukaemia With Cord Blood Stem Cell

CFSE Cell Division Assay Kit

Stem Cells. Part 1: What is a Stem Cell?

NCL Method ITA-14. Analysis of Nanoparticle Effects on Maturation of Monocyte Derived Dendritic Cells In Vitro

Human Peripheral Blood Mononuclear Cell (PBMC) Manual

Chondrogenical Differentiation of Umbilical Cord Lining. Stem Cells

Stem cells for brain cures

US Regulations for Import and Export of Cell Therapy Products

BioArchive Freezing Curve for Cord Blood

LifeNet Health Presented by James Clagett, PhD., Chief Science Officer LifeNet Health - The Best Keep Secret in Regenerative Medicine

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION

Public Cord Blood Banking at the National Cord Blood Program (NCBP)

Corporate Medical Policy Cord Blood as a Source of Stem Cells

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

Human CD4+T Cell Care Manual

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank

STEM CELL LEUCOCYTE BIOLOGY. Setting up of an Umbilical cord blood stem cell bank at Institute of Immunohaematology

Bio Deutschland CEO & CFO-Meeting 29. November Unternehmertum in den Life Sciences am Beispiel der Geschichte von Miltenyi Biotec

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR

Cord Blood: Thawing & Infusion Practical Methods

Peripheral Blood Stem Cell (PBSC) Collections: Why, What, When. Objectives. Sources of Stem Cells

Transcription:

Medical Journal of th e Islamic Republic of Iran Volume 18 Number 3 Fall 1383 November 2004 Basic Science in Medicine ] EXPANSION OF HUMAN CORD BLOOD PRIMITIVE PROGENITORS IN SERUM-FREE MEDIA USING HUMAN BONE MARROW MESENCHYMAL STEM CELLS M. SOLElMANI*, H. MOZDARANI**, A,A. POURFATHOLLAH*, Y. MORTAZAVI*, K. ALIMOGHADDAM***, A. HAJIFATHALI*****, M. NIKOUGOFTAR**** AND Z. ZONOBI***** From the * Hematology Dept.. School of'medical Sciences. Tarbiat Modares University, Tehran, the ** Medical Genetics Dept.. School of Medical Sciences, Tarbiat Modares University, Tehran, the*** Bone Marrow Transplantation Center. Shariati Hospital, Tehran, the**** Iranian Blood Trans(ilsion Organization, Tehran, and ***** Shahid Beheshti Medical Sciences University. Tehran. Irall. ABSTRACT Ex vivo expansion of human umbilical cord blood cells (HUCBC) is explored by several investigators to enhance the repopulating potential of HUCBC. The proliferation and expansion of human hematopoietic stem cells (HSC) in ex vivo culture was examined with the goal of generating a suitable clinical protocol for expanding HSC for patient transplantation. Using primary human mesenchymal stem cells, we established a serum-free culture system to expand human primitive progenitors and transplantable stem cells. Non-enriched cord blood CD34+ cells were cultured on a monolayer of human mesenchymal stem cells in the presence of tlu-ombopoietin (TPO), flt31flk2 ligand (FL), and/or stem cell factor (SCF), interleukin 6 (IL-6), interleukin 3 (IL-3) under serum-free conditions. After I or 2 weeks of culture, cells were examined for clonogenic progenitors and percentage of CD34+ CD38- cells. In the presence of TPO, FL, and SCF, fetal MSC cells supported more than a 35- and 20-fold expansion of CD34+ cells and colonyfolming units in culture after 1 and 2 weeks of incubation, respectively. In addition, LTC-IC assay were expanded more than 7- and 16-fold after 1 and 2 weeks of culture, respectively. UCB-HSC can be expanded in culture to numbers theoretically adequate for safe, rapid engrafiment of adult patients. Additional studies are needed Corresponding author: H.Mozdarani, Ph.D., Dept. of Medical Genetics, School of Medical Sciences, Tarbiat ModalTes University, Tehran, P.O. Box: 14115-11, Iran. Fax: +9821-8006544 Email: mozdaranh@modares.ac.ir 257

Expansion of Human Cord Blood Primitive Progenitors in Serum-Free Media to establish the functional activity of expanded UCB-HSC. This ex vivo expansion system should prove valuable in clinical settings in which stromal cells are available from recipients or stem cell donors. MJIRJ, Vol.18, No.3, 257-263, 2004. Keywords: Ex vivo expansion; Stem cells; Umbilical cord blood; Mesenchymal stem cells. INTRODUCTION Umbilical cord blood (UCB) from related and unrelated donors has emerged as a novel source of stem cells for patients requiring allogeneic transplantation. 1 4 Although UCB contains hematopoietic progenitor cells at a higher frequency and with a higher proliferative capacity than adult-derived bone marrow, the low number of total hematopoietic stem cells (HSCs) contained in one UCB graft limits the potential for rapid hematological recovery in adult patients. 5.6 In an attempt to sh011en the time interval to attain donor-derived hematopoietic recovery after UCB transplantation and allow transplantation of adult recipients, phase I clinical trials have been undertaken to expand UCB in cytokines in vitro prior to infusion. 7-9 However, these clinical trials have failed to demonstrate more rapid hematopoietic recovery in UCB recipients, suggesting that cytokine-based expansion may result in differentia-tion of early self-replicative stem cells. These observa-tions corroborate recent advances in the cellular and molecular mechanisms underlying the regulation of stem ' cell differentiation, indicating that microenvironment or stem cell "niche" is crucial for maintenance of self-renewal capacity of stem cells. 10-14 Mesenchymal stem cells (MSCs) are a nonhematopoietic, well-characterized homogeneous population of adherent skeletal and connective tissue progenitor cells within the bone marrow stroma. 15-17 Importantly, MSCs provide a rich environment of signals, including cytokines, extracellular matrix proteins, adhesion molecules, and cell-cell interactions, controlling the proliferation, survival, and differentiation of early Iymphohematopoietic stem cells. 18, 19 Studies have shown that MSCs secrete, at baseline, interleukin-6 (IL-6), IL-7, IL-8, IL-II, IL-12, IL-14, and IL-15, macrophage-colony-stimulating factor (M-CSF), flt-3 ligand (FL), and stem cell factor (SCF), similar to the cytokines and growth factors expressed by marrow-derived stromal cells. 16 Accordingly, MSCs have been shown, similar to Dexter-type stromal cells, to support long-term culture initiating cell (L TC-IC) colonies during prolonged in vitro bone marrow culture. 19 Importantly, however, IL-l a-stimulated MSCs, but not bone maitow-derived stromal cells, secrete leukemia inhibitory factor (UF), which has been shown to inhibit embryonic stem cell differentiation. 16, 20. 21 For these reasons, we hypothesized that the presence of a feeder layer of human MSCs during short-term UeB cytokine-based expansion may provide a "niche-like" milieu for hematopoietic stem cells and may, thus, inhibit cytokine-driven differentiation of early CD34+ hematopoietic progenitor cells. We, therefore, compared expansion of UCB mononuclear cells (MNCs) during short-term culture in a combination of early-acting cytokines alone with expansion over an MSC feeder layer with added cytokines. MATERIAL AND METHODS Cells UCB was obtained according to institutional guidelines from IS normal full-term deliveries at the Shariati, Madaran and Hedayat Hospitals. Cell processing Buffy coat cells were obtained by centrifugation (400 g for 7 min), and low-density mononuclear cells (MNC, d<1.077 g/ml) were isolated using Ficoll-Paque Plus (Pham1acia Biotech, Uppsala, Sweden). Cells were then resuspended in Iscove Modified Dulbecco Medium (IMDM) sup'plemented with 2% fetal bovine serum (FBS, Gibco). Total numbers of nucleated and viable cells were determined with a hemocytometer using Turck solution and trypan blue stain, respectively. Establishment of human mesenchymal stem cells Bone marrow aspirates were obtained from healthy donors after informed consent. The maitow was mixed with the same volume of PBS, and mononuclear cells were separated by density gradient centrifugation. Washed cells were resuspended in stroma medium (RPMI 1640, Dutch Modification, supplemented with 10% fetal calf serum [FCS], 2 mm L-glutamine, loa IU/mL penicillin, 0.1 mg/ml streptomycin, and 1.0 )lmolll hydrocortisone). 5 x 10 6 cells were placed in 80 cm 2 flasks (Nunc; 258